CONCORDE
Research type
Research Study
Full title
A platform study of DNA damage response inhibitors in combination with conventional radiotherapy in non small cell lung cancer
IRAS ID
282001
Contact name
Alastair Greystoke
Contact email
Sponsor organisation
University of Leeds
Eudract number
2020-000206-28
ISRCTN Number
ISRCTN10142971
Duration of Study in the UK
6 years, 0 months, 1 days
Research summary
Radiotherapy is an effective treatment for patients with non-small cell lung cancer (NSCLC) that has not spread beyond the chest area. Radiotherapy is used as a curative treatment but unfortunately for most patients the cancer can return. Radiotherapy kills cells by damaging their DNA. Cells have the ability to repair that damage, especially the cells of normal tissue. If we can prevent the cancer cells from repairing their DNA, radiotherapy should be more effective causing the cancer cells to die.\n\nWe plan to use new drugs that affect how cells repair DNA damage, called DNA damage response inhibitors (DDRi). These will be given together with radiotherapy to hopefully improve the effectiveness of radiotherapy. We have to work out the most effective and safe dose of this combination treatment. We plan a clinical trial where patients due to have radiotherapy, with the hope of successful treatment that could lead to cure from their cancer or extension of life, will be offered entry onto the study. All patients will receive their radiotherapy, or a single DDRi drug alongside this. Both patients and study doctors will know prior to the start of the actual treatment whether a DDRi will be given, and if so which one. We will follow the patients closely to check for side effects and to assess how their cancer is responding to treatment. We will take blood samples to monitor treatment progress and to try to predict which patients are most likely to benefit from this type of combined treatment.
REC name
Yorkshire & The Humber - Leeds West Research Ethics Committee
REC reference
20/YH/0280
Date of REC Opinion
21 Oct 2020
REC opinion
Favourable Opinion